MiNK Therapeutics, Inc.

INKT

US6036931029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1.01 ^USD	0.00%		+3.08%	-5.61%

May. 14	Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14	MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

MiNK Therapeutics, Inc. Announces Appointment of Jennifer Buell as Chief Executive Officer

January 06, 2022 at 05:29 pm EST

MiNK Therapeutics, Inc. announced that Jennifer Buell resigned as Agenus Inc.'s, President and Chief Operating Officer to become the President and Chief Executive Officer of the company.

Latest news about MiNK Therapeutics, Inc.

Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
MiNK Therapeutics, Inc. announced that it has received $5.8 million in funding	May. 13	CI
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures	May. 13	MT
MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding	May. 12	CI
Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 21	CI
MiNK Therapeutics, Inc. Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	Mar. 06	CI
MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer	Feb. 14	CI
MiNK Therapeutics, Inc. announced that it has received $5 million in funding from Agenus Inc.	Feb. 11	CI
Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	Feb. 06	CI
MiNK?s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	Jan. 30	CI
Transcript : MiNK Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
MiNK Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
MiNK Therapeutics, Inc. Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023	Nov. 03	CI
MiNK Therapeutics, Inc. Announces Resignation of as Director	23-10-17	CI
MiNK Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Index	23-06-23	CI
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Value Index	23-06-23	CI
MiNK Therapeutics Says Cell Product Candidate MiNK-215 Showed 'Potent Anti-Tumor Activity' in Preclinical Trial	23-05-18	MT
HC Wainwright Adjusts MiNK Therapeutics Price Target to $10 From $7, Maintains Buy Rating	23-05-12	MT
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : MiNK Therapeutics, Inc., Q1 2023 Earnings Call, May 11, 2023	23-05-11
Agenus Inc. spin-off 14.5% stake in MiNK Therapeutics, Inc. for $9.1 million.	23-04-30	CI
Evercore ISI Adjusts MiNK Therapeutics' Price Target to $3 From $4, Keeps Outperform Rating	23-03-22	MT

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Sector

Biotechnology & Medical Research

Calendar

02:30pm - American Thoracic Society Conference - Abstract Number: P439

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.01 USD

Average target price

8 USD

Spread / Average Target

+692.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MINK THERAPEUTICS, INC.	-5.61%	35.05M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.17%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research